Cargando…
Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial
BACKGROUND: The mechanisms explaining the clinical benefits of ferric carboximaltose (FCM) in patients with heart failure, reduced or intermediate left ventricular ejection fraction, and iron deficiency remain not fully clarified. The Myocardial‐IRON trial showed short‐term cardiac magnetic resonanc...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075490/ https://www.ncbi.nlm.nih.gov/pubmed/35301854 http://dx.doi.org/10.1161/JAHA.121.022214 |
_version_ | 1784701697157758976 |
---|---|
author | del Canto, Irene Santas, Enrique Cardells, Ingrid Miñana, Gema Palau, Patricia Llàcer, Pau Fácila, Lorenzo López‐Vilella, Raquel Almenar, Luis Bodí, Vicent López‐Lereu, Maria P. Monmeneu, Jose V. Sanchis, Juan Moratal, David Maceira, Alicia M. de la Espriella, Rafael Chorro, Francisco J. Bayés‐Genís, Antoni Núñez, Julio |
author_facet | del Canto, Irene Santas, Enrique Cardells, Ingrid Miñana, Gema Palau, Patricia Llàcer, Pau Fácila, Lorenzo López‐Vilella, Raquel Almenar, Luis Bodí, Vicent López‐Lereu, Maria P. Monmeneu, Jose V. Sanchis, Juan Moratal, David Maceira, Alicia M. de la Espriella, Rafael Chorro, Francisco J. Bayés‐Genís, Antoni Núñez, Julio |
author_sort | del Canto, Irene |
collection | PubMed |
description | BACKGROUND: The mechanisms explaining the clinical benefits of ferric carboximaltose (FCM) in patients with heart failure, reduced or intermediate left ventricular ejection fraction, and iron deficiency remain not fully clarified. The Myocardial‐IRON trial showed short‐term cardiac magnetic resonance (CMR) changes suggesting myocardial iron repletion following administration of FCM but failed to find a significant increase in left ventricular ejection fraction in the whole sample. Conversely, the strain assessment could evaluate more specifically subtle changes in contractility. In this subanalysis, we aimed to evaluate the effect of FCM on the short‐term left and right ventricular CMR feature tracking derived strain. METHODS AND RESULTS: This is a post hoc subanalysis of the double‐blind, placebo‐controlled, randomized clinical trial that enrolled 53 ambulatory patients with heart failure and left ventricular ejection fraction <50%, and iron deficiency [Myocardial‐IRON trial (NCT03398681)]. Three‐dimensional left and 2‐dimensional right ventricular CMR tracking strain (longitudinal, circumferential, and radial) changes were evaluated before, 7 and 30 days after randomization using linear mixed‐effect analysis. The median (interquartile range) age of the sample was 73 years (65–78), and 40 (75.5%) were men. At baseline, there were no significant differences in CMR feature tracking strain parameters across both treatment arms. At 7 days, the only global 3‐dimensional left ventricular circumferential strain was significantly higher in the FCM treatment‐arm (difference: −1.6%, P=0.001). At 30 days, and compared with placebo, global 3‐dimensional left ventricular strain parameters significantly improved in those allocated to FCM treatment‐arm [longitudinal (difference: −2.3%, P<0.001), circumferential (difference: −2.5%, P<0.001), and radial (difference: 4.2%, P=0.002)]. Likewise, significant improvements in global right ventricular strain parameters were found in the active arm at 30 days (longitudinal [difference: −3.3%, P=0.010], circumferential [difference: −4.5%, P<0.001], and radial [difference: 4.5%, P=0.027]). CONCLUSIONS: In patients with stable heart failure, left ventricular ejection fraction <50%, and iron deficiency, treatment with FCM was associated with short‐term improvements in left and right ventricular function assessed by CMR feature tracking derived strain parameters. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03398681. |
format | Online Article Text |
id | pubmed-9075490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90754902022-05-10 Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial del Canto, Irene Santas, Enrique Cardells, Ingrid Miñana, Gema Palau, Patricia Llàcer, Pau Fácila, Lorenzo López‐Vilella, Raquel Almenar, Luis Bodí, Vicent López‐Lereu, Maria P. Monmeneu, Jose V. Sanchis, Juan Moratal, David Maceira, Alicia M. de la Espriella, Rafael Chorro, Francisco J. Bayés‐Genís, Antoni Núñez, Julio J Am Heart Assoc Original Research BACKGROUND: The mechanisms explaining the clinical benefits of ferric carboximaltose (FCM) in patients with heart failure, reduced or intermediate left ventricular ejection fraction, and iron deficiency remain not fully clarified. The Myocardial‐IRON trial showed short‐term cardiac magnetic resonance (CMR) changes suggesting myocardial iron repletion following administration of FCM but failed to find a significant increase in left ventricular ejection fraction in the whole sample. Conversely, the strain assessment could evaluate more specifically subtle changes in contractility. In this subanalysis, we aimed to evaluate the effect of FCM on the short‐term left and right ventricular CMR feature tracking derived strain. METHODS AND RESULTS: This is a post hoc subanalysis of the double‐blind, placebo‐controlled, randomized clinical trial that enrolled 53 ambulatory patients with heart failure and left ventricular ejection fraction <50%, and iron deficiency [Myocardial‐IRON trial (NCT03398681)]. Three‐dimensional left and 2‐dimensional right ventricular CMR tracking strain (longitudinal, circumferential, and radial) changes were evaluated before, 7 and 30 days after randomization using linear mixed‐effect analysis. The median (interquartile range) age of the sample was 73 years (65–78), and 40 (75.5%) were men. At baseline, there were no significant differences in CMR feature tracking strain parameters across both treatment arms. At 7 days, the only global 3‐dimensional left ventricular circumferential strain was significantly higher in the FCM treatment‐arm (difference: −1.6%, P=0.001). At 30 days, and compared with placebo, global 3‐dimensional left ventricular strain parameters significantly improved in those allocated to FCM treatment‐arm [longitudinal (difference: −2.3%, P<0.001), circumferential (difference: −2.5%, P<0.001), and radial (difference: 4.2%, P=0.002)]. Likewise, significant improvements in global right ventricular strain parameters were found in the active arm at 30 days (longitudinal [difference: −3.3%, P=0.010], circumferential [difference: −4.5%, P<0.001], and radial [difference: 4.5%, P=0.027]). CONCLUSIONS: In patients with stable heart failure, left ventricular ejection fraction <50%, and iron deficiency, treatment with FCM was associated with short‐term improvements in left and right ventricular function assessed by CMR feature tracking derived strain parameters. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03398681. John Wiley and Sons Inc. 2022-03-18 /pmc/articles/PMC9075490/ /pubmed/35301854 http://dx.doi.org/10.1161/JAHA.121.022214 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research del Canto, Irene Santas, Enrique Cardells, Ingrid Miñana, Gema Palau, Patricia Llàcer, Pau Fácila, Lorenzo López‐Vilella, Raquel Almenar, Luis Bodí, Vicent López‐Lereu, Maria P. Monmeneu, Jose V. Sanchis, Juan Moratal, David Maceira, Alicia M. de la Espriella, Rafael Chorro, Francisco J. Bayés‐Genís, Antoni Núñez, Julio Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial |
title | Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial |
title_full | Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial |
title_fullStr | Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial |
title_full_unstemmed | Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial |
title_short | Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial |
title_sort | short‐term changes in left and right ventricular cardiac magnetic resonance feature tracking strain following ferric carboxymaltose in patients with heart failure: a substudy of the myocardial‐iron trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075490/ https://www.ncbi.nlm.nih.gov/pubmed/35301854 http://dx.doi.org/10.1161/JAHA.121.022214 |
work_keys_str_mv | AT delcantoirene shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT santasenrique shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT cardellsingrid shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT minanagema shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT palaupatricia shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT llacerpau shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT facilalorenzo shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT lopezvilellaraquel shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT almenarluis shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT bodivicent shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT lopezlereumariap shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT monmeneujosev shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT sanchisjuan shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT morataldavid shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT maceiraaliciam shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT delaespriellarafael shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT chorrofranciscoj shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT bayesgenisantoni shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT nunezjulio shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial AT shorttermchangesinleftandrightventricularcardiacmagneticresonancefeaturetrackingstrainfollowingferriccarboxymaltoseinpatientswithheartfailureasubstudyofthemyocardialirontrial |